PIH15 COST EFFECTIVENESS ANALYSIS OF GOSERELIN EMPIRIC THERAPY FOR DEEP ENDOMETRIOSIS TREATMENT

Dejka M. Araujo, RBF Passos, CPR Souza, AP Silva, Mariana Florêncio Marques
In: Value in Health · 2009 · vol. 12(3) , pp. A164 · doi:10.1016/s1098-3015(10)73883-3 · W2043397345
OA: closed CC0 ⤵ 1 in-corpus citation
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-28 ⓘ

Goserelin empiric therapy for deep endometriosis is cost-effective, with higher costs in the first year but lower overall costs and better quality-adjusted life years over three years compared to standard care.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-09-17T06:32:46.214484+00:00
License: CC0 · commercial use OK